125 related articles for article (PubMed ID: 12720139)
1. Prognostic factors in Waldenstrom's macroglobulinemia: description of the complications during the evolution-preliminary results on 101 patients.
Stalnikiewicz L; Carrotte-Lefebvre I; Detourmignies L; Rose C; Cazin B; Leblond V; Morel P
Semin Oncol; 2003 Apr; 30(2):216-9. PubMed ID: 12720139
[TBL] [Abstract][Full Text] [Related]
2. Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease.
Cesana C; Miqueleiz S; Bernuzzi P; Tresoldi E; Rossi V; D'avanzo G; Filippini D; Morra E
Semin Oncol; 2003 Apr; 30(2):231-5. PubMed ID: 12720142
[TBL] [Abstract][Full Text] [Related]
3. Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: a two-institution study.
Björkholm M; Johansson E; Papamichael D; Celsing F; Matthews J; Lister TA; Rohatiner AZ
Semin Oncol; 2003 Apr; 30(2):226-30. PubMed ID: 12720141
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia.
Merlini G; Baldini L; Broglia C; Comelli M; Goldaniga M; Palladini G; Deliliers GL; Gobbi PG
Semin Oncol; 2003 Apr; 30(2):211-5. PubMed ID: 12720138
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.
Baldini L; Goldaniga M; Guffanti A; Broglia C; Cortelazzo S; Rossi A; Morra E; Colombi M; Callea V; Pogliani E; Ilariucci F; Luminari S; Morel P; Merlini G; Gobbi P
J Clin Oncol; 2005 Jul; 23(21):4662-8. PubMed ID: 16034042
[TBL] [Abstract][Full Text] [Related]
6. Asymptomatic Waldenstrom's macroglobulinemia.
Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
[TBL] [Abstract][Full Text] [Related]
7. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
Weber DM; Dimopoulos MA; Delasalle K; Rankin K; Gavino M; Alexanian R
Semin Oncol; 2003 Apr; 30(2):243-7. PubMed ID: 12720145
[TBL] [Abstract][Full Text] [Related]
8. Transplantation in Waldenstrom's macroglobulinemia--the French experience.
Tournilhac O; Leblond V; Tabrizi R; Gressin R; Senecal D; Milpied N; Cazin B; Divine M; Dreyfus B; Cahn JY; Pignon B; Desablens B; Perrier JF; Bay JO; Travade P
Semin Oncol; 2003 Apr; 30(2):291-6. PubMed ID: 12720155
[TBL] [Abstract][Full Text] [Related]
9. No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years.
Kastritis E; Kyrtsonis MC; Hatjiharissi E; Symeonidis A; Michalis E; Repoussis P; Tsatalas K; Michael M; Sioni A; Kartasis Z; Stefanoudaki E; Voulgarelis M; Delimpasi S; Gavriatopoulou M; Koulieris E; Gika D; Vervesou E; Konstantopoulos K; Kokkini G; Zomas A; Roussou P; Anagnostopoulos N; Economopoulos T; Terpos E; Zervas K; Dimopoulos MA
Am J Hematol; 2011 Jun; 86(6):479-83. PubMed ID: 21509798
[TBL] [Abstract][Full Text] [Related]
10. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
[TBL] [Abstract][Full Text] [Related]
11. [Waldenstrôm's macroglobulinemia. Developmental and prognostic study].
Debre P; Zittoun R; Cadiou M; Bilski-Pasquier G; Bousser J
Sem Hop; 1975 Dec; 51(48):2921-5. PubMed ID: 175503
[TBL] [Abstract][Full Text] [Related]
12. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit.
Kyrtsonis MC; Vassilakopoulos TP; Angelopoulou MK; Siakantaris P; Kontopidou FN; Dimopoulou MN; Boussiotis V; Gribabis A; Konstantopoulos K; Vaiopoulos GA; Fessas P; Kittas C; Pangalis GA
Ann Hematol; 2001 Dec; 80(12):722-7. PubMed ID: 11797112
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic spectrum of Waldenström's macroglobulinemia: a single center experience.
Sajid R; Siddiqui SH; Shaikh U; Adil S
Indian J Pathol Microbiol; 2010; 53(3):490-3. PubMed ID: 20699509
[TBL] [Abstract][Full Text] [Related]
14. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.
Treon SP; Hunter ZR; Matous J; Joyce RM; Mannion B; Advani R; Cook D; Songer J; Hill J; Kaden BR; Sharon D; Steiss R; Leleu X; Branagan AR; Badros A
Clin Cancer Res; 2007 Jun; 13(11):3320-5. PubMed ID: 17545538
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).
Dhodapkar MV; Jacobson JL; Gertz MA; Crowley JJ; Barlogie B
Semin Oncol; 2003 Apr; 30(2):220-5. PubMed ID: 12720140
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
[TBL] [Abstract][Full Text] [Related]
17. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
Anagnostopoulos A; Hari PN; Pérez WS; Ballen K; Bashey A; Bredeson CN; Freytes CO; Gale RP; Gertz MA; Gibson J; Goldschmidt H; Lazarus HM; McCarthy PL; Reece DE; Vesole DH; Giralt SA
Biol Blood Marrow Transplant; 2006 Aug; 12(8):845-54. PubMed ID: 16864055
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Chu L; Musto P; Baron AD; Nunnink JC; Kash JJ; Terjanian TO; Hyman PM; Nawfel EL; Sharon DJ; Munshi NC; Anderson KC
Clin Cancer Res; 2009 Jan; 15(1):355-60. PubMed ID: 19118065
[TBL] [Abstract][Full Text] [Related]
19. Excellent long-term survival of 170 patients with Waldenström's macroglobulinemia treated in private oncology practices and a university hospital.
Hensel M; Brust J; Plöger C; Schuster D; Memmer ML; Franz-Werner J; Feustel HP; Karcher A; Fuxius S; Mosthaf FA; Rieger M; Ho AD; Witzens-Harig M
Ann Hematol; 2012 Dec; 91(12):1923-8. PubMed ID: 22895554
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
Treon SP; Hansen M; Branagan AR; Verselis S; Emmanouilides C; Kimby E; Frankel SR; Touroutoglou N; Turnbull B; Anderson KC; Maloney DG; Fox EA
J Clin Oncol; 2005 Jan; 23(3):474-81. PubMed ID: 15659493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]